Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 128,877

Document Document Title
WO/2018/071537A1
The present disclosure is in the field of pharmaceutical compositions suitable for the treatment of diseases in mammals. The disclosure provides novel compositions comprising non-pathogenic fecal microbes for treating multiple sclerosis ...  
WO/2018/069086A1
Triterpenoid derivatives and compositions comprising said triterpenoids derivatives of Formula (I) are described, wherein R=-C(O)NHOH. Said triterpenoids and compositions show capacity to bind PHD2, stabilize HIF-1α and HIF-2α proteins...  
WO/2018/071656A1
Formulations and compositions for the treatment of migraine headaches, and in general, pain, include riboflavin, magnesium, feverfew and an amino acid, such as 5 -hydroxytryptophan (5-HTP).  
WO/2018/068120A1
The present invention relates to the fields of chemistry, pharmacy, biotechnology and medicine. More particularly, the present invention describes: a compound; the use of said compound; a synthetic intermediate in the preparation of comp...  
WO/2018/071803A1
The disclosure provides a method of eliciting electroencephalographic burst suppression or electroencephalographic suppression in a patient.. the method includes administering to the patient a formulation comprising neurosteroid nanopart...  
WO/2018/068565A1
An application of albiflorin or a pharmaceutically-acceptable salt thereof in production of products for improving the function of the human melatonin system. Albiflorin or a pharmaceutically-acceptable salt thereof, as an endogenous mel...  
WO/2018/071452A1
Provided herein are cannabinoid-containing complex mixtures suitable for use as active pharmaceutical ingredients. The complex mixtures comprise at least a first major cannabinoid, at least a first minor cannabinoid, and optionally at le...  
WO/2018/068295A1
Substituted aryl and heteroaryl ether compounds of the Formula (I) and pharmaceutically acceptable salts thereof, wherein X, R 1, R 2, R 3, L, R 4, L 1, Q, and R 5 are as defined herein. These compounds and pharmaceutically acceptable co...  
WO/2018/068429A1
The present invention relates to a compound represented by structural formula I and a non-toxic, pharmaceutically acceptable salt thereof. R1, R2, R3, and R4 are each methyl (-CH3) or trideuteromethyl (-CD3), and at least one thereof is ...  
WO/2018/068759A1
The present invention relates to a five-membered heteroaryl ring bridged ring derivative, a preparation method therefor and the medical use thereof. In particular, the present invention relates to a new five-membered heteroaryl ring brid...  
WO/2018/071548A1
The present disclosure relates to methods for treating Alzheimer's disease with apilimod and related compositions and methods.  
WO/2018/069312A1
The present invention relates to a modulator of PDE1A and/or PDE1C for use as a medicament, in particular for use in the prevention or treatment of synucleinopathies, such multiple system atrophy, dementia with Lewy bodies, Parkinson's d...  
WO/2018/071893A1
Methods of treating neuropathic pain in spinal cord injured individuals by administering levetiracetam or brivaracetam are described.  
WO/2018/069362A1
The invention provides novel compounds having the general formula (I), wherein R1, R1', R2, R3, R4 are as defined herein, compositions including the compounds and methods of using the compounds.  
WO/2018/068119A1
The present invention relates to the fields of chemistry, pharmacy, biotechnology and medicine. More particularly, the present invention describes: the use of a peptide compound for preparing an anticonvulsant drug; an anticonvulsant pha...  
WO/2018/068297A1
Provided herein are certain substituted N-aryl and N-heteroaryl piperidine compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, L, R4, L1, Q, R5 and R 6 are as defined. The said novel compounds,...  
WO/2018/066532A1
A morphinan derivative exhibiting opioid δ-receptor agonistic activity is provided. A pharmaceutical composition containing the morphinan derivative exhibiting opioid δ-receptor agonistic activity is provided, the pharmaceutical compos...  
WO/2018/066701A1
Provided is a prophylactic or therapeutic agent for frontotemporal lobar degeneration (FTLD), said agent comprising an inhibitor of calcium ion influx into cells. Also provided is a method for screening a prophylactic or therapeutic agen...  
WO/2018/067945A1
Solid state forms of Valbenazine, Valbenazine salts, processes for preparation thereof and pharmaceutical compositions thereof are disclosed. Processes for the preparation of Valbenazine and intermediates in the preparation thereof are f...  
WO/2018/067851A1
Methods of preventing, inhibiting and/or decreasing protein deposits of a human amyloid protein and/or neuroinflammation in the central nervous system by reducing an amount of exposure to a pathogenic bacterial amyloid in the gastrointes...  
WO/2018/064922A1
Application of a GSK3 inhibitor in preparing a drug to treat Niemann-Pick disease type C, the GSK3 inhibitor being capable of significantly improving hematopoiesis and neural stem cell self-renewal and differentiation capability in NPC1 ...  
WO/2018/066676A1
The present invention addresses the problem of examining the physiological activity of selenoneine which is an organic selenium compound and thus finding novel uses thereof. To solve this problem, provided are a composition comprising an...  
WO/2018/066707A1
Provided are: a novel aging inhibitor, soft-tissue calcification inhibitor, and lung tissue destruction inhibitor; food and beverage products, pharmaceutical products, and cosmetic products which include said inhibitors; and a method for...  
WO/2018/064953A1
Use of isopropyl β-(3,4-dihydroxyphenyl)-α-hydroxypropionate (IDHP) in the preparation of a drug or a health product for prevention and treatment of coronary atherosclerosis diseases. The IDHP can also be used to inhibit platelet aggre...  
WO/2018/066427A1
The present invention addresses the problem of providing a composition for preventing and/or treating neurodegenerative diseases and cerebral infarction and a composition for improving learning disorders. Provided is a composition that c...  
WO/2018/065529A1
Provided are novel crystalline forms of a spiro-compoundwhich acts as a muscarinic acetylcholine receptor agonist. In particular, isolated crystalline polymorphs of (S)-2-ethyl-8- methyl-1-thia-4,8-diazaspiro[4.5]decane-3-one are describ...  
WO/2018/067971A1
The present invention relates to carbamoyl phenylalaninol compounds and methods of using the same to treat disorders.  
WO/2018/067579A1
Devices, systems and methods are provided for delivering coffee-derived volatiles to a user, particularly for the treatment of addiction. The coffee volatiles are selected and delivered by devices and systems which allow for concentrated...  
WO/2018/064738A1
The present invention relates to a composition comprising SEQ ID NO: 1 or 2 and one or more pharmaceutically acceptable carriers or diluents. The present invention further relates to the use of the composition as defined in claim 1 or SE...  
WO/2018/067879A1
In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB. In certain aspects, such soluble ALK4:ActRIIB complexes ...  
WO/2018/066718A1
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof : in which n, X, R1, R2, R3 and R4 are as defined in the specification, processes for their preparation, pharmaceutical compositions co...  
WO/2018/067102A1
The invention relates to medical chemistry, in particular to the use of 7-bromo-5-(o-chlorophenyl)-3-propoxy-l,2-dihydro-3H-l,4-benz odiazepin-2-one as a drug which inhibits neuropathic pain without the formation of defects in the gastri...  
WO/2018/059212A1
Provided are a series of compounds reducing SAICAR accumulation, and applications. On the basis of existing protein structure data and small molecule structure data, calculations and analysis are performed using software to screen and ob...  
WO/2018/059531A1
A crystal form of an adenosine A2A receptor antagonist drug, tozadenant, and a preparation method and use thereof. The prepared tozadenant has crystal form CS1, can be used to prepare an adenosine A2A receptor antagonist drug formulation...  
WO/2018/060300A1
The present invention relates to a compound of formula (I), wherein R1 is hydrogen, lower alkyl, lower alkyl substituted by halogen, halogen, lower alkoxy or lower alkoxy substituted by halogen; R may be the same or different, if n = 2 o...  
WO/2018/058296A1
Hydrochloride, phosphate, maleate, citrate and tartrate of TTP488 and crystal forms, preparation methods for the salts of the TTP488 and the crystal forms thereof, pharmaceutical compositions thereof, and uses thereof in the preparation ...  
WO/2018/064377A1
Systems and methods are provided herein for transdermal delivery of an opioid. The opioids can be delivered in a decreasing dose (dose-tapering) manner to minimize withdrawal symptoms and abuse. The systems are also designed to limit a p...  
WO/2018/064649A1
Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1A, R1B, n, R2A, R2B, R3, and R4 are as defined herein. Compounds of the present invention ...  
WO/2018/059213A1
Provided are compounds interfering with SAICAR synthesis, and applications. On the basis of existing protein structure data and small molecule structure data, calculations and analysis are performed using software to screen and obtain co...  
WO/2018/060396A1
A method of attenuating, treating or preventing cognitive aging in an individual who does not have dementia includes administering to the individual a therapeutically effective amount of a composition containing an omega-3 fatty acid and...  
WO/2018/060742A1
The present invention relates to a class of substituted-cyanopyrrolidines of Formula (I) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30)...  
WO/2018/059420A1
The present invention relates to a crystal form of a Sigma-1 receptor antagonist drug, preparation method therefor and use thereof. The crystal form of E52862 hydrochloride salt provided in the present invention, named crystal form H, ca...  
WO/2018/060395A1
A method of attenuating, treating or preventing cognitive aging in an individual who does not have dementia includes administering to the individual a therapeutically effective amount of a composition containing an omega-3 fatty acid, a ...  
WO/2018/064135A1
The present disclosure provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R1-R7 are defined herein. In a further embodiment, these c...  
WO/2018/058984A1
Disclosed are a health-promoting beverage suitable for insomnia sufferers and a manufacturing method thereof. The beverage comprises the following components provided in respective mass fractions: 0.05-0.3 parts of Asian ginseng extract;...  
WO/2018/059214A1
Provided are compounds affecting SAICAR synthesis, and applications. On the basis of existing protein structure data and small molecule structure data, calculations and analysis are performed using software to screen and obtain compounds...  
WO/2018/060732A2
Functional analogs of fenfluramine are provided. The subject fenfluramine functional analogs find use in the treatment of a variety of diseases. For example, methods of treating epilepsy by administering a fenfluramine analog to a subjec...  
WO/2018/064498A1
The disclosure provides methods to prevent, inhibit or treat one or more symptoms associated with epilepsy or encephalopathies in a mammal, comprising: administering to the mammal, e.g., a composition having one of more of compounds of f...  
WO/2018/064436A1
A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a safe and effective amount and the patient achieves PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 week...  
WO/2018/059241A1
Disclosed are an extract with a detoxification pharmaceutical effect and a preparation method therefor. An effective component of the extract has the following chemical structural characteristics: a cholestenol compound with hydroxyl (OH...  

Matches 101 - 150 out of 128,877